WO2007061458A3 - S1p receptor modulating compounds and use thereof - Google Patents

S1p receptor modulating compounds and use thereof Download PDF

Info

Publication number
WO2007061458A3
WO2007061458A3 PCT/US2006/028657 US2006028657W WO2007061458A3 WO 2007061458 A3 WO2007061458 A3 WO 2007061458A3 US 2006028657 W US2006028657 W US 2006028657W WO 2007061458 A3 WO2007061458 A3 WO 2007061458A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
hepatitis
disease
treating
receptor modulating
Prior art date
Application number
PCT/US2006/028657
Other languages
French (fr)
Other versions
WO2007061458A2 (en
Inventor
Ashis K Saha
Anurag Sharadendu
Xiang Y Yu
Jian Lin
Mercedes Lobera
Srinivasa Rao Cheruku
Pini Orbach
Sharon Shacham
Silvia Noiman
Oren Becker
Yael Marantz
Nili Schultz
Dilara Mccauley
Original Assignee
Epix Delaware Inc
Ashis K Saha
Anurag Sharadendu
Xiang Y Yu
Jian Lin
Mercedes Lobera
Srinivasa Rao Cheruku
Pini Orbach
Sharon Shacham
Silvia Noiman
Oren Becker
Yael Marantz
Nili Schultz
Dilara Mccauley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Delaware Inc, Ashis K Saha, Anurag Sharadendu, Xiang Y Yu, Jian Lin, Mercedes Lobera, Srinivasa Rao Cheruku, Pini Orbach, Sharon Shacham, Silvia Noiman, Oren Becker, Yael Marantz, Nili Schultz, Dilara Mccauley filed Critical Epix Delaware Inc
Priority to CA2630714A priority Critical patent/CA2630714C/en
Priority to AU2006317689A priority patent/AU2006317689B2/en
Priority to JP2008542302A priority patent/JP2009520688A/en
Priority to EP06788295A priority patent/EP1965807A4/en
Publication of WO2007061458A2 publication Critical patent/WO2007061458A2/en
Publication of WO2007061458A3 publication Critical patent/WO2007061458A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention relates to compounds of the general formula (I) that have activity as SlP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate SlP receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
PCT/US2006/028657 2005-11-23 2006-07-24 S1p receptor modulating compounds and use thereof WO2007061458A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2630714A CA2630714C (en) 2005-11-23 2006-07-24 S1p receptor modulating compounds and use thereof
AU2006317689A AU2006317689B2 (en) 2005-11-23 2006-07-24 S1P receptor modulating compounds and use thereof
JP2008542302A JP2009520688A (en) 2005-11-23 2006-07-24 S1P receptor modulating compounds and uses thereof
EP06788295A EP1965807A4 (en) 2005-11-23 2006-07-24 S1p receptor modulating compounds and use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US73946605P 2005-11-23 2005-11-23
US60/739,466 2005-11-23
US75380605P 2005-12-22 2005-12-22
US60/753,806 2005-12-22
US78454906P 2006-03-21 2006-03-21
US60/784,549 2006-03-21

Publications (2)

Publication Number Publication Date
WO2007061458A2 WO2007061458A2 (en) 2007-05-31
WO2007061458A3 true WO2007061458A3 (en) 2007-11-15

Family

ID=38067678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028657 WO2007061458A2 (en) 2005-11-23 2006-07-24 S1p receptor modulating compounds and use thereof

Country Status (6)

Country Link
US (2) US7855193B2 (en)
EP (1) EP1965807A4 (en)
JP (1) JP2009520688A (en)
AU (1) AU2006317689B2 (en)
CA (1) CA2630714C (en)
WO (1) WO2007061458A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
CA2595607C (en) 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
AU2006317689B2 (en) * 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
EP2010524A2 (en) * 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
EP2364976B1 (en) * 2007-03-21 2014-10-08 EPIX Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
MX2010002885A (en) * 2007-09-20 2010-04-01 Amgen Inc S1p receptor modulating compounds and use thereof.
GB0722340D0 (en) * 2007-11-14 2007-12-27 Univ Leiden Sphingosine-1-phosphate (S1P) receptor compounds
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
US20090298894A1 (en) * 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
TW201000099A (en) * 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
EP2318415B1 (en) * 2008-07-15 2013-02-20 Sanofi Oxazolopyrimidines as edg-1 receptor agonists
EP2445877B1 (en) * 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
JP2012515787A (en) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー Substituted oxadiazole derivatives as S1P agonists in the treatment of autoimmune and inflammatory diseases
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
US8404672B2 (en) 2009-01-23 2013-03-26 Bristol-Meyers Squibb Company Substituted heterocyclic compounds
CA2749960A1 (en) * 2009-02-10 2010-08-19 Abbott Laboratories Agonists and antagonists of the s1p5 receptor, and methods of uses thereof
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) * 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
UY33176A (en) 2010-01-13 2011-08-31 Sanofi Aventis DERIVATIVES OF OXAZOLOPIRIMIDINE REPLACED IN 2, 5, 7.
AR079981A1 (en) * 2010-01-13 2012-03-07 Sanofi Aventis CARBOXILIC ACID DERIVATIVES THAT INCLUDE AN OXOAZOLOPIRIMIDINE RING 2,5,7- REPLACED
UY33178A (en) * 2010-01-13 2011-08-31 Sanofi Aventis HETEROXYCLIC CARBOXYLIC ACID DERIVATIVES INCLUDING AN OXAZOLOPIRIMIDINE RING 2, 5, 7-REPLACED
UY33180A (en) * 2010-01-14 2011-08-31 Sanofi Aventis HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES THAT INCLUDE A 2,5-REPLACED OXAZOLOPIRIMIDINE RING.
DK2523963T3 (en) 2010-01-14 2014-12-01 Sanofi Sa 2,5-substituted oxazolopyrimidinderivater as edg-1 agonists
CN102884064B (en) 2010-03-03 2016-01-13 艾尼纳制药公司 Prepare the method for S1P1 receptor modulators and crystalline form thereof
ES2548683T3 (en) 2010-04-23 2015-10-20 Bristol-Myers Squibb Company 4- (5-Isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl) -mandelic acid amides as sphingosine-1-phosphate receptor agonists 1
US9187437B2 (en) 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
EP2718279B1 (en) * 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
AU2014202925B2 (en) * 2013-01-10 2015-07-09 Nutritional Therapeutics, Inc. Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders
US9718771B2 (en) 2014-02-28 2017-08-01 Kissei Pharmaceutical Co., Ltd. Aniline derivative, pharmaceutical composition containing same, and use thereof
MX2021011472A (en) 2015-01-06 2022-08-17 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor.
ES2929526T3 (en) 2015-06-22 2022-11-29 Arena Pharm Inc (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor
WO2017131149A1 (en) * 2016-01-29 2017-08-03 小野薬品工業株式会社 Tetrahydronaphthalene derivative
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
EP3687498A1 (en) 2017-09-27 2020-08-05 Novartis AG Parenteral formulation comprising siponimod
CN113354607B (en) * 2020-03-06 2023-12-05 石家庄诚志永华显示材料有限公司 Negative liquid crystal compound, liquid crystal composition, liquid crystal display element and liquid crystal display
CN112675919B (en) * 2021-01-25 2023-06-13 苏州大学 Application of N-heterocyclic carbene-based mixed nickel (II) complex in synthesis of alpha-benzyl benzofuran compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064616A2 (en) * 2001-01-30 2002-08-22 University Of Virgina Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US434785A (en) * 1890-08-19 Oscae a
US3329781A (en) 1965-07-06 1967-07-04 Mallory & Co Inc P R Sequential timing device
DE2812664A1 (en) * 1978-03-22 1979-09-27 Plc Pharma Licences USE OF DILIGNOLS AND DILIGNOL-LIKE COMPOUNDS AS ACTIVE INGREDIENTS OF LEBERTHERAPEUTICA
US4767896A (en) 1985-09-03 1988-08-30 Molex Incorporated Stamped circuitry assembly
JP2657324B2 (en) 1989-04-19 1997-09-24 大塚製薬株式会社 Phenylcarboxylic acid derivatives having a hetero ring
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
DE4405378A1 (en) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhesion receptor antagonists
JPH10204059A (en) 1997-01-22 1998-08-04 Ono Pharmaceut Co Ltd Phenylsulfonamide derivative
JP3802653B2 (en) 1997-05-21 2006-07-26 オリンパス株式会社 Stereoscopic image display device
US6384061B1 (en) * 1997-07-26 2002-05-07 Lg Chemical Ltd. Hydantoin compounds and methods related thereto
MXPA01013326A (en) * 2001-02-14 2002-08-26 Warner Lambert Co Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors.
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
AU2003215396B2 (en) * 2002-02-25 2010-04-08 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7199142B2 (en) 2002-06-17 2007-04-03 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
US7820682B2 (en) * 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
CA2506799A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
DE10300398A1 (en) * 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of substituted 2-phenylbenzimidazoles as a drug
CA2524027C (en) 2003-05-19 2013-03-19 Irm Llc Immunosuppressant compounds and compositions
BRPI0410439A (en) * 2003-05-19 2006-06-06 Irm Llc immunosuppressive compounds and compositions
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CA2576388A1 (en) * 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
ES2526544T3 (en) 2004-12-13 2015-01-13 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medical use thereof
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
AU2006317689B2 (en) 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
EP2010524A2 (en) * 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
EP2364976B1 (en) 2007-03-21 2014-10-08 EPIX Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
MX2010002885A (en) 2007-09-20 2010-04-01 Amgen Inc S1p receptor modulating compounds and use thereof.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064616A2 (en) * 2001-01-30 2002-08-22 University Of Virgina Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1965807A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US9126932B2 (en) 2008-07-23 2015-09-08 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US9522133B2 (en) 2008-07-23 2016-12-20 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US9108969B2 (en) 2008-08-27 2015-08-18 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US9175320B2 (en) 2010-01-27 2015-11-03 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
US9447041B2 (en) 2010-01-27 2016-09-20 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Also Published As

Publication number Publication date
CA2630714C (en) 2014-01-14
US7855193B2 (en) 2010-12-21
AU2006317689A8 (en) 2008-07-03
US20070173487A1 (en) 2007-07-26
WO2007061458A2 (en) 2007-05-31
AU2006317689B2 (en) 2013-07-25
EP1965807A4 (en) 2010-10-27
US20110059945A1 (en) 2011-03-10
EP1965807A2 (en) 2008-09-10
JP2009520688A (en) 2009-05-28
US20080064677A9 (en) 2008-03-13
AU2006317689A1 (en) 2007-05-31
CA2630714A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2007061458A3 (en) S1p receptor modulating compounds and use thereof
WO2007109334A3 (en) Sip receptor modulating compounds and use thereof
MX2010002885A (en) S1p receptor modulating compounds and use thereof.
ATE540035T1 (en) SPIRO-2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES THEREOF
MX2020006045A (en) Tlr7/8 antagonists and uses thereof.
WO2009016253A3 (en) Cyanomethyl substituted n-acyl tryptamines
WO2011150156A3 (en) Heteroaryl compounds and methods of use thereof
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008096870A1 (en) Aza-bridged-ring compound
WO2006063178A3 (en) Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof
WO2005121965A3 (en) Distributed storage network
EA201492250A1 (en) Heterocyclic Compound
WO2005005530A3 (en) Stabilizing composition for chlorine-containing polymers
WO2008147812A3 (en) 4' substituted compounds having 5-ht6 receptor affinity
WO2006120010A3 (en) Dibenzocycloheptane compounds and pharmaceuticals containing these compounds
WO2011017165A8 (en) Method of preventing renal disease and treating symptoms thereof
WO2006119072A3 (en) Binder metal with shield insert
MX337558B (en) Hydrophobic, functionalized particles.
WO2013092778A3 (en) Chemical compounds
TW200700151A (en) Organic halogen compound decomposing agent
WO2012050228A3 (en) Pest controlling composition and method for controlling pest
WO2008111295A1 (en) Agent for prevention and/or treatment of systemic lupus erythematosus
WO2003082197A3 (en) Immunosuppressant compounds, methods and uses related thereto
WO2009065947A3 (en) Pharmaceutical composition containing a zeolite/algae or zeolite/emulsion combination for the treatment of aids
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/006603

Country of ref document: MX

Ref document number: 2008542302

Country of ref document: JP

Ref document number: 2630714

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006317689

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006317689

Country of ref document: AU

Date of ref document: 20060724

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006788295

Country of ref document: EP